Trials / Active Not Recruiting
Active Not RecruitingNCT04398459
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
A Phase II, Multicenter, Open-label Trial to Determine the Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 6 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib | Each recruited subject will accept Ibrutinib treatment. |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
- First posted
- 2020-05-21
- Last updated
- 2024-09-25
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04398459. Inclusion in this directory is not an endorsement.